In conclusion, this study, combining GCT patient data characteristics and functional mechanistic cell line investigations, illustrates the role of TP53 status in cisplatin resistance in GCTs, related to the anatomical location associated with molecular constitution. This evidence concerns the gene TP53 and granular cell tumor.